# Study Guide: Fertility Preservation in People With Cancer This study guide provides a comprehensive overview of the **2025 ASCO Guideline Update on Fertility Preservation in People With Cancer**. It is designed to assist healthcare professionals and students in mastering the clinical recommendations, biological risks, and ethical considerations surrounding reproductive health in oncology. --- ## Key Concepts and Recommendations ### 1. The Core Mandate of Care Fertility preservation (FP) is an essential component of care for children and reproductive-aged adults with cancer. Advances in cancer treatments have improved survival rates, making long-term reproductive health a priority. * **Timing:** Discussions regarding FP should be initiated as early as possible, ideally before cancer-directed therapy begins. * **Documentation:** All discussions regarding fertility risks and options must be documented in the medical record throughout the care trajectory and into survivorship. * **Referral:** Patients interested in FP, or even those who are uncertain, should be referred promptly to reproductive specialists. ### 2. Risk Factors and Stratification Cancer treatments pose differential risks to fertility based on the type and dose of therapy, as well as patient age. * **High-Risk Agents:** Alkylating agents, platinum exposure, radiation to the ovaries or testes, and hematopoietic cell transplantation are significant threats. * **Biological Sex Definitions:** In these guidelines, "male" refers to individuals born with testes and "female" refers to those born with ovaries, focusing on reproductive anatomy at birth. * **Dose-Dependent Damage:** * For females, radiation doses as low as 2 Gy carry a 1%–5% risk of Acute Ovarian Failure (AOF), while doses $\ge$ 24 Gy in patients aged 1–20 years carry a $\ge$ 50% risk. * For males, alkylating agents and radiation can cause significant genetic damage to sperm, particularly if collected soon after treatment initiation. ### 3. Established Fertility Preservation Methods | Population | Established Methods | Experimental/Investigational Methods | | :--- | :--- | :--- | | **Males** | Sperm cryopreservation (sperm banking); Testicular sperm extraction (TESE) for postpubertal males. | Testicular tissue cryopreservation (TTC) for prepubertal males. | | **Females** | Embryo cryopreservation; Mature oocyte cryopreservation; Ovarian tissue cryopreservation (OTC); Ovarian transposition; Conservative gynecologic surgery. | In vitro maturation (IVM) (Emerging); Uterine transposition. | | **Children** | Semen/oocyte cryopreservation (pubertal); OTC (prepubertal females). | TTC (prepubertal males). | ### 4. Special Considerations for Females * **Ovarian Stimulation:** "Random start" protocols allow for oocyte retrieval without delaying cancer treatment by 2–3 weeks. For hormone-sensitive cancers (e.g., breast cancer), aromatase inhibitor-based protocols (letrozole) are used to minimize estrogen exposure. * **Ovarian Suppression:** Gonadotropin-releasing hormone agonists (GnRHa) should **not** replace established FP methods but can be used as an adjunct in breast cancer or for menstrual suppression in oncologic emergencies (e.g., leukemia). * **Post-Treatment FP:** This may be offered to survivors who did not undergo pretreatment FP or those who face accelerated age-related fertility decline due to their history of cancer. ### 5. Ethical and Health Equity Issues * **Assent and Consent:** FP in children requires parental consent and, where appropriate, the child’s assent. * **Disparities:** Studies show significant disparities in FP usage based on race, ethnicity, socioeconomic status, and geographic location. Only up to 4% of women with cancer may engage in FP, with lower usage among non-Hispanic Black and rural populations. * **Cost:** Utilization of FP is linked to medical financial hardship. While 17 states and D.C. have mandated some insurance coverage for FP, levels of coverage vary significantly. --- ## Short-Answer Practice Questions 1. **What is the "gold standard" outcome for evaluating the effectiveness of fertility preservation?** * *Answer:* Live (healthy) birth. 2. **Why is it strongly recommended that males collect sperm samples before initiating any antineoplastic therapy?** * *Answer:* Because the quality of the sample and sperm DNA integrity can be compromised after even a single treatment, posing a higher risk of genetic damage. 3. **Which fertility preservation method is the only established option for prepubertal females?** * *Answer:* Ovarian tissue cryopreservation (OTC). 4. **How long does it typically take for ovarian stimulation and oocyte retrieval in female patients?** * *Answer:* 2 to 3 weeks from the initiation of ovarian stimulation. 5. **What is the role of letrozole in the treatment of patients with hormone-sensitive cancers undergoing FP?** * *Answer:* It is used in stimulation protocols to keep estrogen levels low, alleviating concerns about cancer progression or recurrence. 6. **Under what specific circumstances is testicular sperm extraction (TESE) recommended?** * *Answer:* It is recommended for pubertal and postpubertal males who are unable to provide a semen sample through ejaculation. 7. **What is the primary risk associated with reintroducing cryopreserved ovarian tissue in leukemia survivors?** * *Answer:* There is a theoretical risk of reintroducing malignant cells (minimal infiltrative disease) back into the patient. 8. **What is the recommended approach for hormonal gonadoprotection in male patients?** * *Answer:* Hormonal suppression therapy should not be offered to males, as it has been proven ineffective for preserving fertility. --- ## Essay Prompts for Deeper Exploration 1. **Multidisciplinary Integration:** Discuss the roles of the various members of an oncology team (oncologists, nurses, social workers, reproductive specialists) in ensuring guideline-concordant fertility care. How does a lack of communication between these specialties impact patient outcomes? 2. **The Ethics of Pediatric Oncofertility:** Analyze the ethical complexities of performing invasive procedures (like OTC or TTC) on prepubertal children who cannot provide legal consent. Address the balance between the "uncertain benefit" of future fertility and the "immediate risk" of delaying life-saving cancer treatment. 3. **Barriers to Equitable Care:** Evaluate how social determinants of health—such as geography, insurance mandates, and structural racism—create disparities in access to fertility preservation. What proactive steps can clinicians take to mitigate these disparities according to the ASCO guidelines? 4. **Established vs. Emerging Techniques:** Compare and contrast embryo cryopreservation with In Vitro Maturation (IVM). Why is IVM currently classified as "emerging," and what data points are still required for it to become an "established" method? --- ## Glossary of Important Terms * **Acute Ovarian Failure (AOF):** The immediate loss of ovarian function following gonadotoxic therapy. * **Anti-Müllerian Hormone (AMH):** A biomarker used to assess ovarian reserve; post-treatment levels typically increase for 2–3 years before plateauing. * **Azoospermia:** The absence of motile (and sometimes any) sperm in the semen. * **Embryo Cryopreservation:** The process of fertilizing oocytes with sperm and freezing the resulting embryos; currently has the strongest effectiveness data for females. * **Gonadotoxicity:** The quality of being toxic to the gonads (testes or ovaries), often a side effect of chemotherapy and radiation. * **In Vitro Maturation (IVM):** An emerging technique involving the culture of immature oocytes to reach the stage where they can be fertilized. * **Oocyte Cryopreservation:** The process of freezing unfertilized eggs; an established method for females who do not have a male partner or have ethical objections to embryo freezing. * **Ovarian Tissue Cryopreservation (OTC):** The surgical removal and freezing of ovarian cortex tissue for future transplantation; the only option for prepubertal females. * **Ovarian Transposition (Oophoropexy):** A surgical procedure to move the ovaries out of the field of planned radiation to protect them from damage. * **Posthumous Reproduction:** The use of stored gametes (sperm or eggs) for procreation after the death of the donor; requires clear legal and ethical directives. * **Spermatogonial Stem Cells (SSC):** Cells in the testes that produce sperm; the target of experimental preservation in prepubertal males. * **Testicular Sperm Extraction (TESE):** A surgical procedure to recover sperm directly from the testicular tissue.